Media

Vicore Pharma to Present at Upcoming Investor Conferences

Hemab Therapeutics Receives FDA Breakthrough Therapy Designation for Sutacimig in Glanzmann Thrombasthenia

Oncorena receives regulatory approval in France and Portugal to initiate the Oncorella-1 clinical study

Kivu Bioscience Appoints Brunilda Shtylla as Chief Business Officer

Vicore Pharma to Present at Upcoming Investor Conferences

Oncopeptides publishes disclosure document regarding rights issue 

Mahzi Therapeutics Announces First Patient Dosed in Phase 1/2 UNITE Study of MZ-1866 for Pitt Hopkins Syndrome

Kivu Bioscience Presents KIVU-305 Preclinical Data at World ADC London 2026 and Advances into Phase 1 Clinical Trial

Positrigo – Launch of the BrainPET Accelerator Program

Oncopeptides carries out a rights issue of approximately SEK 200 million